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Abstract. This review summarises the evidence for the
role of myocardial perfusion scintigraphy (MPS) in pa-
tients with known or suspected coronary artery disease.
It is the product of a consensus conference organised by
the British Cardiac Society, the British Nuclear Cardiolo-
gy Society and the British Nuclear Medicine Society and
is endorsed by the Royal College of Physicians of Lon-
don and the Royal College of Radiologists. It was used
to inform the UK National Institute of Clinical Excel-
lence in their appraisal of MPS in patients with chest
pain and myocardial infarction. MPS is a well-estab-
lished, non-invasive imaging technique with a large body
of evidence to support its effectiveness in the diagnosis
and management of angina and myocardial infarction. It
is more accurate than the exercise ECG in detecting
myocardial ischaemia and it is the single most powerful
technique for predicting future coronary events. The high
diagnostic accuracy of MPS allows reliable risk stratifi-
cation and guides the selection of patients for further in-
terventions, such as revascularisation. This in turn allows
more appropriate utilisation of resources, with the poten-
tial for both improved clinical outcomes and greater
cost-effectiveness. Evidence from modelling and obser-
vational studies supports the enhanced cost-effectiveness
associated with MPS use. In patients presenting with sta-
ble or acute chest pain, strategies of investigation involv-
ing MPS are more cost-effective than those not using the
technique. MPS also has particular advantages over al-
ternative techniques in the management of a number of
patient subgroups, including women, the elderly and
those with diabetes, and its use will have a favourable
impact on cost-effectiveness in these groups. MPS is al-
ready an integral part of many clinical guidelines for the
investigation and management of angina and myocardial
infarction. However, the technique is underutilised in the
UK, as judged by the inappropriately long waiting times
and by comparison with the numbers of revascularisat-
ions and coronary angiograms performed. Furthermore,
MPS activity levels in this country fall far short of those
in comparable European countries, with about half as
many scans being undertaken per year. Currently, the
number of MPS studies performed annually in the UK is
1,200/million population/year. We estimate the real need
to be 4,000/million/year. The current average waiting
time is 20 weeks and we recommend that clinically ap-
propriate upper limits of waiting time are 6 weeks for
routine studies and 1 week for urgent studies.
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Introduction
Background
Coronary heart disease (CHD) is a major cause of mor-
tality and morbidity in Europe and its management con-
sumes a large proportion of national healthcare budgets.
New imaging technologies have added to the immediate
costs of investigation but they also have the potential to
reduce overall costs, by virtue of their greater diagnostic
and prognostic accuracy. This allows a more informed
selection of therapy, which in turn can lead to a better
clinical outcome.
Myocardial perfusion scintigraphy (MPS) is an estab-
lished imaging technique that is already an integral part
of the management of CHD and is included in a number
of professional guidelines. Its most important applica-
tions are in the diagnosis of CHD, prognostication, se-
lection for revascularisation and assessment of acute cor-
onary syndromes, and it is of special value in some pa-
tient subgroups.
In this consensus document we review the evidence
supporting the clinical effectiveness and cost-effective-
ness of MPS and we assess its potential to improve pa-
tient care in the UK. The current utilisation of MPS is re-
viewed and targets for service improvements are pro-
posed.
Description of process for consensus meeting
Representatives of the British Cardiac Society (BCS),
the British Nuclear Cardiology Society (BNCS) and the
British Nuclear Medicine Society (BNMS) met at a con-
sensus conference in January 2003 to review the evi-
dence for the clinical and cost-effectiveness of MPS and
to draft a document for submission to the National Insti-
tute for Clinical Excellence (NICE). The document was
a submission for the NICE appraisal of MPS in the diag-
nosis and management of angina and myocardial infarc-
tion. The final document was endorsed by the three soci-
eties and also by the Royal College of Physicians of
London (RCP) and the Royal College of Radiologists
(RCR).
What is MPS?
MPS was developed in the 1970s and has been used 
increasingly in clinical cardiology since the 1980s. Tech-
nical developments that have fuelled this recent increase
are single-photon emission tomographic imaging (SPET),
pharmacological stress and ECG-gated imaging.
The technique involves intravenous injection of small
amounts of a radioactive tracer, usually during some
form of cardiovascular stress. The three commercially
available tracers are thallium-201 thallous chloride (thal-
lium), technetium-99m 2-methoxy-isobutyl-isonitrile
(MIBI) and technetium-99m 1,2-bis[bis(2-ethoxyethyl)
phosphino] ethane (tetrofosmin). These are avidly ex-
tracted by cardiac myocytes and hence their initial myo-
cardial distribution reflects a combination of the distribu-
tion of myocytes and perfusion. Comparison of images
following stress and rest injections of tracer (or follow-
ing redistribution for thallium) allows myocardial viabil-
ity and perfusion to be assessed independently.
Pharmacological stress, using a vasodilator such as
adenosine or a beta sympathetic agonist such as dobuta-
mine, allows patients who cannot achieve maximal car-
diovascular stress on a treadmill to be studied, and this is
a particularly valuable aspect of the technique that is rel-
evant to between one-third and one-half of patients.
SPET is the preferred imaging technique, whereby the
camera rotates around the patient over 10–20 min and
the resulting set of planar projection images are recon-
structed into a three-dimensional stack of tomographic
slices through the myocardium. The tomograms are dis-
played using a colour scale to provide a semi-quantita-
tive assessment of regional tracer uptake, and compari-
son with databases of normal appearances allows objec-
tive assessment of the presence, depth and extent of ab-
normalities. The stress and rest images are normally sep-
arated by 3–4 h but the total patient contact time for
stress, injection and image acquisition is approximately
45 min.
Homogeneous myocardial uptake of tracer indicates
normal myocardium and perfusion and hence the ab-
sence of clinically significant infarction or coronary ste-
nosis. A defect in the stress images that normalises in the
rest images (a reversible defect) indicates an inducible
perfusion abnormality and normally corresponds to a
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significant coronary stenosis. A defect in both stress and
rest images (a fixed defect) indicates an area with loss of
viable myocardium such as after myocardial infarction.
The site, extent and depth of these abnormalities are
readily assessed and hence the technique is valuable for
the diagnosis of CHD, for assessing its severity, which in
turn is related to prognosis, and for assessing global and
regional myocardial function from ECG-gated moving
images.
Safety
MPS is non-invasive and safe, particularly in comparison
with invasive investigation, which it can sometimes re-
place. The complication rate of dynamic exercise is well
established from treadmill exercise electrocardiography
as at most 0.01% deaths and 0.02% morbidity [1] and
similar rates have been observed with pharmacological
stress [2, 3, 4]. These low rates are at least two orders of
magnitude less than the risk of underlying CHD and so,
except in patients with unstable CHD or other contrain-
dications to stress, the risk is not normally considered
significant.
The radiation exposure to the patient is 10 mSv for a
1,000 MBq tetrofosmin study, 12 mSv for a 1,000 MBq
MIBI study and 18 mSv for an 80 MBq thallium study
[5]. A 10 mSv exposure is equivalent to 5 years of natu-
ral background radiation; it is similar to the exposure
from computed X-ray tomography (CT) and coronary
angiography [6] and it produces a 1 in 1,800 risk of can-
cer 10–20 years after the exposure [7]. Although this is
higher than the risk of the stress test, it is small alongside
the lifetime risk of cancer in the general population (1 in
3), and it is of even lesser importance in the elderly and
those with known CHD, the population that is most com-
monly referred for MPS.
Coronary angiography is complicated by death in
0.1% of cases and by non-fatal events such as myocar-
dial infarction, stroke and emergency bypass grafting in
2% [8]. Lesser complications such as bleeding, dissec-
tion and thrombosis of the vascular access site occur in
0.5% [8].
Diagnosis
Coronary angiography and myocardial perfusion
MPS is the only widely available method of assessing
myocardial perfusion directly. It therefore has a clear
role in the diagnosis of CHD in patients presenting with
chest pain. An inducible perfusion abnormality indicates
impaired perfusion reserve, which in turn usually corre-
sponds to epicardial coronary obstruction. The site,
depth and extent of the abnormality provide diagnostic
and management information that cannot be determined
reliably from other tests such as the ECG. Conversely,
normal stress MPS indicates the absence of coronary ob-
struction and hence of clinically significant disease. It is
important to note that normal perfusion does not exclude
non-obstructive coronary disease, but such disease is un-
likely to be related to symptoms and is not prognostical-
ly important (see section “Prognosis”).
Coronary angiography is the standard technique for
assessing epicardial coronary anatomy and MPS is the
standard technique for assessing myocardial perfusion.
Although the anatomical extent of disease is best demon-
strated by coronary angiography, MPS provides a com-
plementary assessment of its physiological significance
and hence information on important features such as en-
dothelial function, small vessel function and collaterali-
sation, in addition to the haemodynamic significance of
epicardial stenoses. Discrepancies between coronary
anatomy and myocardial perfusion do not necessarily in-
dicate a failure in the assessment of either; instead they
indicate the complexity of the relationship. Complete ac-
curacy of MPS to predict the findings at coronary angi-
ography is neither expected nor necessary for clinical
management, and when MPS is used for the diagnosis of
CHD it is not being used purely to predict the presence
of epicardial coronary disease. Nevertheless, the coro-
nary angiogram is an accepted standard for imaging the
coronary arteries and functional tests such as MPS are
commonly compared with angiography.
Diagnostic accuracy of MPS
Many studies have assessed the diagnostic accuracy of
MPS for the detection of coronary heart disease, but they
are of variable size and quality. Tables 1, 2, 3 and 4
summarise the findings according to the four main forms
of stress and also grade the quality of the studies accord-
ing to accepted principles [9, 10]. The highest quality
score is 3, when the study involves a clearly defined
population, when it avoids verification bias and when
MPS is interpreted independently of angiography. A
quality score of 2 fulfils two of these criteria and a score
of 1 only one criterion. An additional criterion of quality
is the exclusion of patients with previous infarction since
the most relevant population is the diagnostic study,
where MPS may be less sensitive than in patients with
previous infarction and abnormal resting images.
Sensitivity and specificity
Because of the variation in study size, quality and de-
sign, we have avoided giving weighted averages of sen-
sitivity and specificity in the above tables. Specificity in
particular varies between studies depending upon patient
population, nature of reporting and referral bias (see sec-
tion “Factors affecting observed diagnostic perfor-
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mance”), and averages do not give a clear indication of
the performance of the technique.
In the largest single study of 2,560 patients randomis-
ed to each of the three tracers and using mainly adeno-
sine stress (the ROBUST study, UK based), overall sen-
sitivity in the subset of patients undergoing angiography
was 91% and specificity 87%, with no significant differ-
ence between the three tracers [55]. In general terms,
Table 1. Diagnostic accuracy of exercise MPS for the detection of ≥50% coronary stenosis defined angiographically
Author, year [ref.] No. Tracer Analysis MI excluded Quality Sens (%) Spec (%) Acc (%)
Tamaki, 1984 [11] 104 201Tl Q Botha 2 98 91 96
DePasquale, 1988 [12] 210 201Tl Q Botha 2 95 74 92
Fintel, 1989 [13] 135 201Tl V No 2 83 – –
Iskandrian, 1989 [14] 193 201Tl V Yes 2 86 62 79
Maddahi, 1989 [15] 110 201Tl Q Botha 3 95 56 88
Mahmarian, 1990 [16] 296 201Tl Q Botha 3 87 87 87
Van Train, 1990 [17] 242 201Tl Q Botha 2 94 43 85
Coyne, 1991 [18] 100 201Tl V No 2 81 74 77
Quinones, 1992 [19] 112 201Tl V Yes 1 77 81 78
Chae, 1993 [20] 243 201Tl V No 3 71 63 69
Grover-McKay, 1994 [21] 18 201Tl V No 1 91 86 89
Tamaki, 1994 [22] 25 201Tl V No 1 95 33 88
Ho, 1997 [23] 51 201Tl V Botha 3 76 77 76
Kiat, 1990 [24] 53 MIBI Q Botha 2 94 80 92
Pozzoli, 1991 [25] 75 MIBI V No 1 84 88 85
Solot, 1993 [26] 78 MIBI V No 2 96 74 90
Marwick, 1994 [27] 86 MIBI V Yes 2 73 70 72
Van Train, 1994 [28] 124 MIBI Q Botha 2 89 36 81
Tamaki, 1994 [22] 26 Tetro V No 1 96 67 92
Heo, 1994 [29] 23 Tetro V No 2 87 – –
Benoit, 1996 [30] 30 Tetro V Yes 2 81 89 83
Shanoudy, 1998 [31] 26 Tetro V No 2 96 – –
201Tl, Thallium-201 thallous chloride; MIBI, technetium-99m 2-me-
thoxy-isobutyl-isonitrile; Tetro, technetium-99m 1,2-bis[bis(2-eth-
oxyethyl) phosphino] ethane; V, visual analysis; Q, quantitative anal-
ysis; MI, myocardial infarction; Sens, sensitivity; Spec, specificity;
Acc, accuracy
a Accuracy reported in full group and in subset without infarction;
figures in table relate to whole patient group
Table 2. Diagnostic accuracy of dipyridamole MPS for the detection of ≥50% (or ≥70%a) coronary stenosis defined angiographically
Author, year [ref.] No. Tracer Analysis MI excluded Quality Sens (%) Spec (%) Acc (%)
Francisco, 1982 [32]a 75 201Tl Q No 2 90 96 92
Huikuri, 1988 [33]a 93 201Tl V No 2 96 75 94
Go, 1990 [34] 202 201Tl V Bothb 3 76 80 77
Mendelson, 1992 [35]a 79 201Tl V Bothb 2 90 – –
Cramer, 1994 [36] 38 201Tl V No 3 90 71 87
Grover-McKay, 1994 [21] 18 201Tl V Unknown 1 91 100 94
Ho, 1995 [37] 54 201Tl V No 3 98 73 93
Watanabe, 1997 [38] 53 201Tl V Yes 2 80 72 77
Tartagni, 1991 [39] 30 201Tl; V No 2 100 75 97
MIBI
Miller, 1997 [40] 244 MIBI V Bothb 2 91 28 81
Schillaci, 1997 [41] 40 MIBI V Yes 1 95 72 85
Soman, 1997 [42] 27 MIBI V No 3 90 66 89
Ogilby, 1998 [43] 26 MIBI V No 2 90 100 92
Santoro, 1998 [44]a 60 MIBI V Yes 3 97 89 93
He, 1997 [45] 64 Tetro V No 2 85 54 80
Abbreviations as defined in Table 1 and list of abbreviations
a ≥70% coronary stenosis
b Accuracy reported in full group and in subset without infarction;
figures in table relate to whole patient group
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Table 3. Diagnostic accuracy of adenosine MPS for the detection of ≥50% coronary stenosis defined angiographically
Author, year [ref.] No. Tracer Analysis MI excluded Quality Sens (%) Spec (%) Acc (%)
Nguyen, 1990 [46] 60 201Tl V No 2 92 100 93
Verani, 1990 [47] 45 201Tl Q No 2 83 94 87
Coyne, 1991 [18] 100 201Tl V Bothb 2 83 76 79
Nishimura, 1991 [48] 101 201Tl V Bothb 3 84 84 84
Allman, 1992 [49] 76 201Tl Q Yes 3 85 38 80
Pennell, 1995 [50] 226 201Tl V No 3 96 78 92
Mohiuddin, 1996 [51] 202 201Tl Q No 3 90 86 89
Amanullah, 1993 [52] 40 MIBI V No 2 94 100 95
Marwick, 1993 [53] 97 MIBI V Yes 2 86 71 80
Jamil, 1999 [54] 32 MIBI V No 2 75 – –
Kapur, 2002 [55]a 2,560 201Tl, V Yes 2 91 87 91
MIBI, 
Tetro
Table 4. Diagnostic accuracy of dobutamine MPS for the detection of ≥50% (or ≥70%a) coronary stenosis defined angiographically
Author, year [ref.] No. Tracer Analysis MI excluded Quality Sens (%) Spec (%) Acc (%)
Pennell, 1991 [56] 50 201Tl V No 2 97 80 94
Warner, 1993 [57] 16 201Tl V No 2 93 100 94
Hays, 1993 [58] 67 201Tl Q No 2 86 90 87
Huang, 1997 [59] 93 201Tl Q No 3 90 81 87
Huang, 1998 [60] 110 201Tl V Yes 3 82 82 82
Caner, 1997 [61] 29 201Tl; V Uncertain 3 89 70 83
MIBI
Gunalp, 1993 [62] 27 MIBI V Yes 2 94 89 93
Forster, 1993 [63] 21 MIBI V Yes 3 83 89 86
Marwick, 1993 [53] 97 MIBI V Yes 2 80 74 77
Marwick, 1993 [64] 217 MIBI Q Yes 3 76 67 73
Mairesse, 1994 [65] 129 MIBI V Yes 3 76 65 72
Marwick, 1994 [27] 82 MIBI V Yes 2 65 68 66
Senior, 1994 [66] 61 MIBI V No 3 95 71 88
Di Bello, 1996 [67] 45 MIBI V Yes 3 87 86 87
Iftihar, 1996 [68] 38 MIBI V No 2 79 90 82
Kisacik, 1996 [69] 69 MIBI V No 3 96 64 86
Slavich, 1996 [70] 46 MIBI V Yes ? 82 83 83
San Roman, 1998 [71] 92 MIBI Q Yes 3 87 70 82
Santoro, 1998 [44]a 60 MIBI Q Yes 3 91 81 87
Elhendy, 1998 [72] 70 MIBI V No ? 64 72 67
Abbreviations as defined in Table 1 and list of abbreviations
a≥70% coronary stenosis
Abbreviations as defined in Table 1 and list of abbreviations
a 89% of studies with adenosine and 137 patients undergoing angi-
ography
b Accuracy reported in full group and in subset without infarction;
figures in table relate to whole patient group
however, the sensitivity of exercise MPS for detecting
angiographically defined CHD is consistently above
70%, but in the better designed studies it is in the region
of 85–90% [13, 14, 15]. Reported specificity varies from
33% to 100% but in the better quality studies it is in the
region of 70–75% [26, 27], with values up to 94% when
ECG-gated imaging is used [73].
For pharmacological stress studies using thallium, a
number of good quality studies show that sensitivity is in
the region of 90% for both dipyridamole [21, 32, 35, 36]
and adenosine [46, 51] and that specificity is 75–80%
[18, 33, 34, 39, 50] although some studies have reported
even higher values (95-100%) [21, 32, 46]. Results ob-
tained using MIBI are similar to those obtained using
thallium [40, 41, 43, 44, 52, 53, 54]. When dobutamine
is used with thallium, the sensitivity is in the region of
90% while the specificity ranges from 81% to 100% [56,
57, 58, 59, 60]. When dobutamine is used with MIBI,
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most studies have shown that the sensitivity is above
80% [53, 61, 62, 63, 66, 67, 69, 70, 71] but the specifici-
ty ranges from 64% to 90% [68, 69].
Fewer diagnostic studies have been performed using
tetrofosmin because of its more recent introduction com-
mercially. For exercise studies using tetrofosmin, sensi-
tivity and specificity range from 81% to 96% [22, 30,
31] and from 67% to 91% [22, 30] respectively.
Factors affecting observed diagnostic performance
When the reference standard for diagnosis, in this case
coronary angiography, is not used in all patients and re-
ferral to angiography is more likely when MPS is abnor-
mal, then the findings are affected by referral bias and
specificity appears falsely low [74, 75, 76, 77, 78, 79,
80, 81]. Indeed, if only patients with abnormal MPS un-
dergo angiography then the observed sensitivity will be
100% and the specificity 0%. Normalcy is therefore a
better parameter for defining the performance of a test in
patients without disease. It is the percentage of studies
that are normal in a population with a low likelihood of
CHD, defined clinically. Normalcy has been reported in
a number of studies (Table 5) and the weighted average
of normalcy is 89%.
Another form of referral bias is when mainly high-
likelihood patients are referred for MPS, which increases
apparent sensitivity because of the higher proportion of
patients with more severe disease [75, 83]. Analysis of
the tables above shows that mean sensitivity reduces
from 92% to 87% when studies including patients with
prior infarction are excluded. Sensitivity is also higher
with more extensive and severe disease and lower with
single-vessel disease or in those with stenoses involving
branches of the major vessels (91% versus 83%).
The intensity of stress is also a confounding factor
and several studies have shown that sensitivity is related
to the intensity of exercise [14, 23, 84]. Anti-angina
medication reduces sensitivity using dynamic exercise
[85, 86] and medication should ideally be discontinued
before diagnostic studies [87]. It is less clear whether
medication reduces diagnostic sensitivity using vasodila-
tor stress but reduced sensitivity has been observed [88].
Tracer activity below the diaphragm is commonly
seen with MIBI and tetrofosmin and this can reduce ac-
curacy in some studies [40, 45]. Other causes of artefact
that can reduce specificity are photon attenuation and
scatter, patient motion, low count statistics, reconstruc-
tion artefact or processing errors. Experienced practitio-
ners can normally identify these problems and they
maintain sensitivity and specificity not only by recognis-
ing common abnormal appearances but also by taking
account of the clinical circumstances. Thus, studies
where images are interpreted in the absence of clinical
information can lead to relatively poor diagnostic perfor-
mance [73]. Image quantification can help inter-observer
variability but its value for accuracy is less clear, with
some studies showing greater accuracy with quantifica-
tion [11, 32, 47] and others no difference [12, 16, 17, 28,
83]. Correction for photon attenuation and scatter, using
simultaneous or sequential transmission imaging, is also
now feasible but its value is not yet clearly established
[89, 90, 91, 92, 93].
ECG-gating is another option that improves diagnos-
tic accuracy and it is now used routinely in many cen-
tres. This aids the distinction between true perfusion ab-
normality and artefact [94, 95, 96] and it provides addi-
tional prognostic information from global and regional
left ventricular function [97].
Despite their different physical and imaging charac-
teristics, all three radiotracers have comparable diagnos-
tic accuracies for detecting CAD. This can be seen in the
above tables and it has been confirmed clinically in a
large randomised study (the ROBUST study) [55]. How-
ever, the technetium-99m labelled tracers have myocar-
dial uptake curves that plateau at lower levels of hypera-
emia than thallium, and it has been suggested that they
may not perform well when used with vasodilator stress
[98]. However, several studies with MIBI indicate that
diagnostic accuracy is not compromised with vasodila-
tors [36, 41, 42, 43, 44, 52, 53]. Studies using tetrofos-
min with vasodilator stress are less consistent, with some
reporting good diagnostic accuracy [55] and others
Table 5. Normalcy values in
patients with a low pre-test
likelihood of CHD
Author, year [ref.] No. Tracer Stress Normalcy (%)
Iskandrian, 1989 [14] 131 201Tl Exercise 94
Maddahi, 1989 [15] 52 201Tl Exercise 86
Van Train, 1990 [17] 76 201Tl Exercise 82
Coyne, 1991 [18] 45 201Tl Exercise, adenosine 80
Kiat, 1992 [82] 55 201Tl Exercise 89
Nishimura, 1991 [48] 39 201Tl Exercise 92
Nishimura, 1991 [48] 39 201Tl Adenosine 95
Van Train, 1994 [28] 37 201Tl Exercise 81
Kiat, 1990 [24] 8 MIBI Exercise 88
Heo, 1994 [29] 61 MIBI Exercise 95
Weighted average 543 89
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showing reduced sensitivity in patients with mild disease
[31, 99]. Reduced sensitivity has also been reported in
some but not all studies of MIBI performed with dobuta-
mine [69, 72].
Overall accuracy of MPS
In summary, therefore, despite the availability of three
different tracers, several forms of stress and the con-
founding factors described above, it is reasonable for the
purposes of this appraisal to consider MPS as a generic
test without regard for the different ways in which it can
be performed. When this is done, good quality studies
show a sensitivity for CHD defined angiographically as
high as 90% and a normalcy of 89%.
Prognosis
MPS and prognosis
For many patients with CHD, the assessment of progno-
sis, or likelihood of future cardiac events, is an essential
step in choosing between medical management and re-
vascularisation. The power of MPS for predicting future
coronary events has been demonstrated in a large num-
ber of high-quality studies and in many thousands of pa-
tients. It is perhaps the area of nuclear cardiology where
the evidence is most strong [100, 101, 102].
The most important variables that predict the likeli-
hood of future events are the extent and severity of induc-
ible ischaemia [103] but other predictors are increased
lung uptake of thallium [104], stress-induced ventricular
dilatation[105] and left ventricular ejection fraction [106,
107]. In general, markers of left ventricular dysfunction
tend to predict cardiac mortality and inducible ischaemia
predicts acute coronary syndromes [108, 109]. MPS has
incremental prognostic value even after clinical assess-
ment, exercise electrocardiography and coronary angiog-
raphy [97, 110]. In other words, patients who appear to be
high risk after coronary angiography can be separated in-
to higher and lower risk groups by MPS.
Patients with abnormal MPS have on average an an-
nual event rate (cardiac death or myocardial infarction)
of 6.7% (Table 6). In contrast, it is an almost universal
finding that normal MPS indicates good clinical out-
come, irrespective of other features such as the presence
of non-obstructive coronary disease. Thus 16 studies per-
formed between 1994 and 2001, which reported 20,983
patients with normal MPS and a mean follow-up of 28
months, showed a rate of cardiac death or myocardial in-
farction of 0.7% per year, a rate similar to that of an
asymptomatic population (Table 7) [111]. Similar find-
ings have recently been reported in a multicentre registry
of 4,728 patients [112]. Thus, whether minor coronary
artery disease is present or not, further investigation can
be avoided.
Patients with chest pain and a normal resting ECG
who are able to exercise will often undergo exercise
electrocardiography as the initial test for diagnosis and
risk stratification. Intermediate risk results, however, oc-
cur in approximately 30–55% cases [128, 179] and it is
in these patients that perfusion imaging has its greatest
role. It has incremental prognostic value within this risk
category, and there is a closer association of subsequent
coronary angiographic data with the results of the perfu-
sion scan than with the exercise electrocardiogram [126].
When the resting ECG is abnormal, exercise testing
can provide some prognostic information from the exer-
Table 6. Prognostic value of MPS in definite or suspected CHD (adapted from reference [111])
Year Author [ref.] No. Agent Abnormal Mean HE HE with HE with RR
MPS (%) F/U (m) (%/yr) abnormal normal 
MPS (%/yr) MPS (%/yr)
2001 Galassi [113] 459 Tetro 77 37 2.5 3.0 0.9 3.25
1999 Vanzetto [114] 1,137 201Tl 66 72 1.5 2.0 0.6 3.53
1998 Hachamovitch [108] 5,183 MIBI/201Tl 43 21.4 3.0 5.9 0.8 7.50
1998 Olmos [115] 225 201Tl 49 44.4 1.8 2.7 0.9 2.86
1998 Alkeylani [116] 1,086 MIBI 62 27.6 3.4 5.0 0.6 8.92
1997 Snader [117] 3,400 201Tl 21 ~24 1.6 (ACM) ~3.8 (ACM) ~1.0 (ACM) 3.75
1997 Boyne [118] 229 MIBI 32 19.2 2.2 5.1 0.8 6.23
1997 Geleijnse [119] 392 MIBI 67 22 6.0 8.7 0.8 10.67
1995 Heller [120] 512 MIBI 58 12.8 4.6 6.9 1.3 5.29
1994 Machecourt [121] 1,926 201Tl 63 33 2.0 2.9 0.5 6.23
1994 Kamal [122] 177 201Tl 83 22 4.3 5.2 0 –
1994 Stratmann [123] 534 MIBI 66 13 10.1 14.3 1.6 9.12
1994 Stratmann [124] 521 MIBI 60 13 4.2 6.7 0.5 14.60
ACM, All-cause mortality; HE, hard event (cardiac death or non-fatal MI); RR, relative risk; other abbreviations as defined in Table 1
and list of abbreviations
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cise duration but ECG changes are unhelpful. In contrast,
MPS maintains its prognostic power [130].
Prognosis can be assessed in patients who are unable
to exercise using MPS with pharmacological stress. The
risk of cardiac death in these patients is higher than in
patients able to exercise, most likely because of higher
underlying likelihood of disease [131].
MPS as the gatekeeper to angiography
Because of its prognostic power, MPS can be used as the
gatekeeper to coronary angiography. Bateman and col-
leagues showed that referral to coronary angiography af-
ter normal, mild to moderately abnormal and severely
abnormal perfusion scans was 3.5%, 9% and 60% re-
spectively [132]. Importantly, a policy of selective refer-
ral to coronary angiography based upon high-risk find-
ings is defensible, patients with mild to moderate abnor-
malities managed medically having outcomes compara-
ble to those undergoing invasive evaluation and subse-
quent angioplasty [133].
Risk assessment before non-cardiac surgery
MPS can provide useful information about cardiac risk
in patients requiring non-cardiac surgery although these
patients are generally at low risk and the predictive value
of a normal perfusion study is greater than that of an ab-
normal study. In a meta-analysis of 3,718 patients under-
going vascular and other surgery, the positive predictive
value of inducible ischaemia for peri-operative death or
infarction was 12.9% compared with a negative predic-
tive value of 98.6%, a risk ratio of 9.1 (Table 8).
The ACC/AHA algorithm for pre-operative risk as-
sessment considers initially the urgency for surgery, its
inherent cardiac risk, the patient’s risk factors and exer-
cise tolerance [134]. Patients with only minor clinical
predictors (advanced age, abnormal resting ECG, previ-
ous stroke or uncontrolled hypertension) who require
low- to moderate-risk surgery are at low risk and do not
require further investigation. Patients with intermediate
clinical predictors (mild angina, prior infarction, treated
heart failure or diabetes) or with minor predictors and re-
duced exercise tolerance need further assessment before
moderate- or high-risk surgery. Patients at high clinical
risk (recent infarction or unstable angina, uncontrolled
heart failure or significant arrhythmias) require investi-
gation before any sort of surgery. When further investi-
gation is required, the choice lies primarily between the
exercise ECG and MPS, the latter usually being reserved
for patients with an abnormal resting ECG or who are
unable to exercise. In general, patients identified as low
risk can undergo surgery without further investigation.
All other patients require aggressive medical manage-
ment at the time of surgery, intervention usually being
reserved for those in whom revascularisation is indicated
regardless of the need for surgery.
Table 7. Prognostic value of normal MPS in patients presenting with stable chest pain (adapted from reference [111])
Year Author [ref.] No. Agent Normal MPS Mean F/U HE with 
(%) (months) normal MPS 
(% per yr)
2001 Galassi [113] 459 Tetro 23 37 0.9
2000 Groutars [125] 236 Tetro/201Tl 100 25 0.4
1999 Gibbons [126] 4,473 201Tl/MIBI 100 36 0.6
1999 Soman [127] 473 MIBI 100 30 0.2
1999 Vanzetto [114] 1,137 201Tl 34 72 0.6
1998 Hachamovitch [108] 5,183 MIBI/201Tl 57 21.4 0.8
1998 Olmos [115] 225 201Tl 51 44.4 0.9
1998 Alkeylani [116] 1,086 MIBI 38 27.6 0.6
1997 Snader [117] 3,400 201Tl 79 ~24 ~1.0 (ACM)
1997 Boyne [118] 229 MIBI 68 19.2 0.8
1997 Geleijnse [119] 392 MIBI 33 22 0.8
1995 Heller [120] 512 MIBI 42 12.8 1.3
1994 Machecourt [121] 1,926 201Tl 37 33 0.5
1994 Kamal [122] 177 201Tl 17 22 0
1994 Stratmann [123] 534 MIBI 34 13 1.6
1994 Stratmann [124] 521 MIBI 40 13 0.5
Total 20,963 53 28.3 0.7
ACM, All-cause mortality; HE, hard event (cardiac death or non-fatal MI); RR, relative risk; other abbreviations as defined in Table 1
and list of abbreviations
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Special groups
Women
Cardiovascular disease is the commonest cause of death
in women in Europe [162]. Underlying mechanisms are
complex, although increasing prevalence of risk factors
and greater life expectancy play an important role. The
prevalence of risk factors is higher in women than in
men, and triglycerides, HDL-cholesterol, cigarette smok-
ing and diabetes are particularly important [163]. In ad-
dition to the obvious hormonal influences in women,
there are gender-related structural differences in plaque
composition (more cellular fibrous tissue) [164] and in-
cidence of sub-clinical atherosclerosis [165]. These fac-
tors may explain, in part, why women present with
symptoms some 10 years later than men, are less likely
to complain of chest pain and are more likely to suffer
upper abdominal pain, dyspnoea, nausea and fatigue.
Diagnosis
In men, the exercise ECG is the conventional gatekeeper
for invasive investigation and possible intervention when
assessing known or potential CHD. In women, however,
the exercise ECG has at best only moderate accuracy for
the detection of CHD [166]. In contrast, MPS is equally
accurate for the detection of disease in women and men
[167].
Prognosis
Although initial prognostic data were acquired for large-
ly male populations aged less than 70 years, recent stud-
ies have established that the prognostic power of normal
and abnormal myocardial perfusion images is equally
strong in men and women. In fact women with severe
abnormalities may have a worse outcome than men with
Table 8. MPS for preoperative assessment of cardiac risk (adapted from reference [134])
Year Author [ref.] No. Inducible MI/death PPV NPV
ischaemia (%)
(%)
Vascular surgery
1985 Boucher [135] 48 16 (33) 3 (6%) 19% (3/16) 100% (32/32)
1987 Cutler [136] 116 54 (47) 11 (10%) 20% (11/54) 100% (60/60)
1988 Fletcher [137] 67 15 (22) 3 (4%) 20% (3/15) 100% (56/56)
1988 Sachs [138] 46 14 (31) 2 (4%) 14%(2/14) 100% (24/24)
1989 Eagle [139] 200 82 (41) 15 (8%) 16% (13/82) 98% (61/62)
1990 McEnroe [140] 95 34 (36) 7 (7%) 9% (3/34) 96% (44/46)
1990 Younis [141] 111 40 (36) 8 (7%) 15% (6/40) 100% (51/51)
1991 Mangano [142] 60 22 (37) 3 (5%) 5% (1/22) 95% (19/20)
1991 Strawn [143] 68 n/a 4 (6%) n/a 100% (21/21)
1991 Watters [144] 26 15 (58) 3 (12%) 20% (3/15) 100% (11/11)
1992 Hendel [145] 327 167 (51) 28 (9%) 14% (23/167) 99% (97/98)
1992 Lette [146] 355 161 (45) 30 (8%) 17% (28/161) 99% (160/162)
1992 Madsen [147] 65 45 (69) 5 (8%) 11% (5/45) 100% (20/20)
1993 Brown [148] 231 77 (33) 12 (5%) 13% (10/77) 99% (120/121)
1993 Kresowik [149] 170 67 (39) 5 (3%) 4% (3/67) 98% (64/65)
1994 Baron [150] 457 160 (35) 22 (5%) 4% (7/160) 96% (195/203)
1994 Bry [151] 237 110 (46) 17 (7%) 11% (12/110) 100% (97/97)
1995 Koutelou [152] 106 47 (44%) 3 (3%) 6% (3/47) 100% (49/49)
1995 Marshall [153] 117 55 (47%) 12 (10%) 16% (9/55) 97% (33/34)
1997 Van Damme [154] 142 48 (34%) 3 (2%) n/a n/a
Non-vascular surgery
1990 Camp [155] 40 9 (23) 6 (15%) 67% (6/9) 100% (23/23)
1991 Iqbal [156] 31 11 (41) 3 (11%) 27% (3/11) 100% (20/20)
1992 Coley [157] 100 36 (36) 4 (4%) 8% (3/36) 98% (63/64)
1992 Shaw [158] 60 28 (47) 6 (10%) 21% (6/28) 100% (19/19)
1993 Takase [159] 53 15 (28) 6 (11%) 27% (4/15) 100% (32/32)
1994 Younis [160] 161 50 (31) 15 (9%) 18% (9/50) 98% (87/89)
1996 Stratmann [161] 229 67 (29%) 10 (4%) 6% (4/67) 99% (91/92)
Weighted average 3,718 246 (7%) 12.1% (186/1,397) 98.6% (1,549/1,571)
MI, Myocardial infarction; NPV, negative predictive value; PPV, positive predictive value; n/a, not available
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severe abnormalities. In a study of 1,394 women fol-
lowed for a mean of 20 months, MPS was able to stratify
women according to risk irrespective of presenting like-
lihood of CHD [168]. In a further study of 3,402 women,
normal MPS predicted a favourable outcome and the ex-
tent of inducible ischaemia was strongly associated with
mortality [169]. Three-year survival reduces from 99%
to 85% as the number of vascular territories with perfu-
sion abnormality increases from zero to three [170]. This
prognostic power is additional to clinical information
and information from the exercise ECG [20, 168, 171,
172].
Acute myocardial infarction
Women with acute myocardial infarction have an in-
creased probability of surviving to reach hospital but
they have a higher mortality at 30 days than men [173].
MPS is helpful for triage in the general population pre-
senting with acute chest pain but there are few data on
MPS in this setting in women [174].
The elderly
An ageing population leads to increasing use of NHS 
resources. Because the elderly have reduced capacity 
for exercise and frequently have abnormal resting
ECGs, the exercise ECG is of limited use [175] but
MPS using pharmacological stress is effective and it 
retains its diagnostic and prognostic power [176, 177,
178, 179].
Diabetes
Diabetes is a vascular disease. Type 2 diabetes is associ-
ated with the same cluster of risk factors as cardiovascu-
lar disease and life expectancy is reduced by 8–10 years
in the 40- to 70-year age group. Type 1 diabetes carries
the same mortality even though it is not associated with
the same risk factors [180].
Several studies have demonstrated the prognostic
power of MPS in diabetic patients [181, 182, 183]. In a
study of 1,371 patients, normal MPS was associated with
an incidence of cardiovascular events of 1–2% per year,
while the incidence was greater than 7% per year in
those with severe perfusion abnormalities [184]. Multi-
variate analysis has shown that MPS abnormalities, reti-
nopathy and duration of diabetes are independent predic-
tors of cardiac events [185]. It has been suggested that
MPS might be used to screen for CHD in high-risk
asymptomatic diabetics, and a multicentre clinical trial
to evaluate the effectiveness of this approach is in pro-
gress [186].
Ethnicity
South Asians resident in the UK have a 40–50% higher
mortality from CHD than the population average, the
reason for which is not clearly defined. MPS is equally
effective in South Asians and Afro-Caribbeans for the
diagnosis of CHD and assessment of prognosis, although
account should be taken of the different CHD profiles
[187, 188, 189].
Revascularisation
Before revascularisation
MPS is superior to the exercise ECG for the detection of
myocardial ischaemia and it provides independent and
incremental information in predicting future cardiac
events [190, 191]. This applies in almost all clinical cir-
cumstances, including suspected CHD, stable angina, af-
ter stabilisation of acute coronary syndromes and before
non-cardiac surgery. It also applies before and after myo-
cardial revascularisation and hence the technique is valu-
able in assessing the need for and the outcome of inter-
vention [192].
In patients with ischaemic left ventricular dysfunc-
tion, MPS can define the need for revascularisation by
determining the presence and extent of ischaemia and of
viable but hibernating myocardium [193, 194, 195, 196]
(Table 9). This is particularly the case with severe left
ventricular dysfunction, when MPS can predict the 
improvement in left ventricular function and the over-
all prognosis [181, 197, 198]. MPS is most helpful 
when left ventricular ejection fraction is severely re-
duced, and in these high-risk patients rest imaging alone
can detect viable myocardium [199, 200, 201, 202, 203,
204].
After revascularisation
MPS is more sensitive than the exercise ECG in detect-
ing inducible ischaemia if angina recurs after revascu-
larisation, and it can be used to evaluate the success of
revascularisation [205]. It is an accurate technique for
detecting bypass graft occlusion or stenosis, with sensi-
tivity and specificity of 81% and 79% respectively [206,
207, 208] (Table 10).
Table 9. Indications for MPS before revascularisation
Detection, localisation and quantification of ischaemia 
as a cause of symptoms
Detection of silent ischaemia
Risk stratification and prognostication
Detection and quantification of viable/hibernating myocardium
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Chest pain and exercise electrocardiography are
largely unhelpful in identifying patients at risk after re-
vascularisation [209] but MPS is of proven value [197,
208, 210, 211, 212]. In the NIH-sponsored Emory An-
gioplasty versus Surgery Trial (EAST), inducible perfu-
sion abnormalities 1 year after revascularisation separat-
ed the patients into low- and high-risk groups [213]. This
prognostic power lasts for a considerable time and the
technique is valuable for long-term follow-up [209, 211,
214, 215, 216, 217].
Following percutaneous intervention the situation is
more complex. Normal perfusion excludes restenosis
and indicates a good prognosis [212] but inducible perfu-
sion abnormalities can be seen in the first 6 weeks after
angioplasty in the absence of restenosis and these are
thought to correspond to abnormal small vessel or endo-
thelial function [218]. Thereafter an abnormal perfusion
study is predictive of adverse cardiac events [219].
Acute coronary syndromes
Cardiological management of patients with acute coro-
nary syndromes (ACS) was an important implication of
the National Service Framework for CHD [220].The
joint BCS and RCP guidelines for the management of
ACS without persistent ST segment elevation [221] have
recommended that dedicated units for the assessment of
low-risk patients with acute chest pain should be evalu-
ated based upon evidence from the USA [222] and the
UK [223]. High-risk patients, including those with raised
troponin, persistent symptoms and/or ST segment chang-
es or adverse exercise ECG results, should have urgent
coronary angiography, with the intention of revasculari-
sation to improve outcome. However, if symptoms settle
on medical therapy and there are no clinical markers of
high risk, MPS can be used for risk stratification [224,
225]. This concept applies across the spectrum of ACS,
from patients without diagnostic ECG changes, to unsta-
ble angina (UA), to non-ST segment elevation myocar-
dial infarction (NSTEMI) and to ST segment elevation
myocardial infarction (STEMI). Risk assessment, togeth-
er with appropriate aggressive secondary prevention, is
particularly helpful in the UK situation of uneven access
to revascularisation, and allows for appropriate prioriti-
sation of patients.
Imaging in the emergency department
Relationship of imaging and clinical outcome
There is a substantial body of literature evaluating rest
MPS in patients presenting with acute chest pain and
suspected ACS. When tracer is injected during pain,
MPS has 96% sensitivity for severe coronary stenosis
compared with 35% sensitivity for the resting ECG [226]
and as much as 20% of the myocardium can be abnormal
when the ECG is normal or non-diagnostic [227]. Pa-
tients with abnormal MPS have a substantially higher
likelihood of adverse cardiac events during hospitalisat-
ion and follow-up (Fig. 1) [228]. Conversely, MPS has a
negative predictive value for ruling out myocardial in-
farction of 99% or more in all studies (Fig. 2) [228, 229,
230]. Consequent reduction in the missed infarction rate
from 1.8% to 0.1% has important implications for patient
outcome and the cost-effectiveness of management [231,
232].
Table 10. Indications for MPS after revascularisation
After percutaneous coronary intervention
Suboptimal results
Recurrence of symptoms or suspected restenosis
Multivessel disease with incomplete revascularisation
Procedural complications
Assessing the effects of intervention if required 
for occupational reasons
After coronary artery bypass grafting
Incomplete revascularisation or poor distal vessels
Recurrence of symptoms or suspected graft occlusion
Procedural complications
Assessing the effects of intervention if required 
for occupational reasons
Fig. 1. The incremental value of resting MPS to predict cardiac
events in emergency department patients with suspected ACS.
Chi-square (y-axis) measures the strength of the association be-
tween individual factors added in incremental fashion (x-axis) and
unfavourable cardiac events. RF, Risk factors; CP, chest pain.
(Adapted from reference [232])
Non-ST segment elevation myocardial infarction 
and unstable angina
There is general agreement that the half of the patients
with UA and high-risk clinical features should undergo
prompt coronary angiography, but there is less agree-
ment on the management of the other half who are at in-
termediate or low clinical risk, as originally defined by
the US Agency for Health Care and Policy Research
Guidelines [237]. MPS is known to be able to separate
these patients into a low-risk group that might be man-
aged conservatively without angiography and a higher
risk group that might benefit from intervention, and re-
cent randomised trials support this strategy [238]. Ac-
cordingly, MPS in this setting is a class 1 indication un-
der AHA/ACC guidelines [234].
The main benefit of intervention in ACS in RITA 3
was in reducing refractory angina, which could have
been identified by a conservative strategy [239], and a
recent meta-analysis has suggested no clear superiority
of early intervention [240]. These data therefore suggest
that a conservative strategy in which stabilised patients
are risk-stratified by MPS offers similar outcomes with
fewer invasive procedures. This concept is relevant for
UK practice and the use of MPS as a gatekeeper to angi-
ography in stabilised ACS might reduce the trend to-
wards diminishing marginal returns of early invasive
management.
A recent retrospective analysis of the TIMI-IIIB data
has shown that a simple clinical score is able to classify
over half the population as low risk [241], suggesting a
substantial group of patients in whom MPS might be
used for further risk stratification. In TACTICS-
TIMI18, the troponin positive subgroup (60% of the to-
tal population) had a larger reduction in death or myo-
cardial infarction with the early invasive strategy, leav-
ing 40% who might benefit from non-invasive risk
stratification using MPS [242]. The UK guidelines
[221] suggest a conservative strategy even for patients
with an abnormal troponin providing that symptoms
have settled for 48 h and there are no other high-risk
features.
ST segment elevation myocardial infarction
The majority of patients who survive the initial acute
stage of myocardial infarction will have a relatively sta-
ble course, and current guidelines recommend non-inva-
sive risk assessment before hospital discharge [243,
244]. MPS with vasodilator stress can be performed
safely as early as 3 days after infarction, before the ma-
jority of recurrent clinical events occur, and can be used
to guide early discharge [245]. ECG-gated imaging also
provides a measure of left ventricular function, which
has additional value in predicting outcome (Fig. 3)
[246]. Coronary angiography does not improve a prog-
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Comparison with enzymatic markers 
of myocardial damage
Acute MPS has the potential to identify ACS much earli-
er in its evolution than enzyme markers, with an early
sensitivity for myocardial infarction of 92% compared
with only 39% for troponin I assayed at the same time
[233].
Randomised trials
Two randomised controlled trials have shown that MPS
can improve triage decisions in the emergency depart-
ment. Stowers and colleagues randomised 46 patients
with acute chest pain and non-diagnostic ECGs to an
MPS-guided strategy or conventional care; the former
incurred less cost, shorter hospital and intensive care
stays, and fewer cardiac catheterisations but there was no
difference in outcome at 30 days [234]. The ERASE trial
(Emergency Room Assessment of Sestamibi for Evalua-
tion of Chest Pain) randomised 2,127 similar patients to
similar strategies and showed fewer admissions of pa-
tients shown ultimately not to have ACS (20% reduction,
odds ratio 0.68, P<0.001) [235]. This benefit applied in-
dependently of age, gender, risk factors or imaging expe-
rience.
Suspected acute myocardial infarction
The impetus for chest pain assessment units in an emer-
gency admissions area is supported by the fifth joint re-
port of the RCP and BCS on provision of cardiothoracic
services [236].
Fig. 2. The predictive value for death and infarction after initial
stabilisation of unstable angina with medical therapy, according to
whether the exercise ECG (Ex-ECG) is negative (light grey) or
positive (dark grey) and whether MPS does not (light grey) or
does (dark grey) show inducible ischaemia. Summary of three
studies adapted from reference [238]
273
European Journal of Nuclear Medicine and Molecular Imaging Vol. 31, No. 2, February 2004
nostic model that includes clinical, ejection fraction and
MPS data [247].
Travin and colleagues used MPS in 134 patients with-
in 14 days of uncomplicated infarction and showed that
the extent of ischaemia was the only significant predictor
of future cardiac events on Cox regression analysis
(Fig. 4) [248]. Similarly, Basu and colleagues in the UK
showed a hazard ratio of 8.1 (95% CI 2.7–23.8,
P<0.001) for coronary events comparing patients with
and without inducible perfusion abnormalities [249]. Pa-
tients with no evidence of inducible ischaemia within the
infarct zone, even in the presence of residual stenosis of
the infarct-related artery, were found by Ellis and col-
leagues to derive no benefit from angioplasty [250].
Cost-effectiveness
Several principles underlie why a more accurate diag-
nostic test with additional prognostic information, such
as MPS, can be more cost-effective even if it is more ex-
pensive than an alternative test such as the exercise ECG
(Table 11) [251].
For instance, Fig. 5 illustrates that when a patient with
a presenting likelihood of CHD of 50% has an abnormal
exercise ECG the post-test likelihood of disease is 73%,
which is not sufficiently high to be confident of the diag-
nosis. A subsequent abnormal MPS gives a likelihood of
96% but if the same patient had gone directly to MPS the
post-test likelihood would have been 90%, which should
be sufficiently high to diagnose the presence of CHD, de-
pending upon the clinical circumstances.
Fig. 3. Cox regression models displaying 1-year post-infarction
risk of cardiac event according to LV ejection fraction and total
LV ischaemia. Diagonal lines, Lines of equal risk. Risk increases
as total LV ischaemia increases and LV ejection fraction decreas-
es. LV ejection fraction and scintigraphic results for each of 92 pa-
tients who did (solid circles) or did not (open circles) have subse-
quent cardiac events over the entire follow-up period are plotted
against calculated risk at 1 year. (From reference [246])
Table 11. Principles of cost-effective diagnosis and management
of CHD using MPS
High sensitivity excludes disease more accurately 
and avoids the need for a secondary test that could arise 
if a less accurate primary test were used
High sensitivity leads to fewer false negative tests 
and avoids the cost of future events in undiagnosed patients 
with disease
High specificity reduces the number of false positive tests 
and consequent downstream testing
Additional prognostic information avoids the need 
for further prognostic testing and focusses high-cost 
interventional care on patients with advanced disease 
and with most to gain in terms of clinical outcome
Fig. 4. Hard event rates over a mean of 15 months after myocar-
dial infarction according to the number of segments with inducible
ischaemia by MPS. Patients with more extensive ischaemia are at
progressively higher risk (P=0.017). (From reference [248])
Fig. 5. Pre- and post-test likelihood of CHD calculated using
Bayesian principles for the exercise ECG and MPS, using sensi-
tivities of 68% and 92% respectively and specificities of 77% and
88% respectively. The curved lines from top to bottom represent
MPS+, ECG+, ECG− and MPS−
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Costs
True costs, reflecting consumption of resources, are dif-
ficult to estimate. Some analyses of cost-effectiveness
have used prices as a surrogate for cost, which may be
valid from the perspective of the patient or referring cli-
nician, but is less helpful from the perspective of the
healthcare provider. Two studies have estimated cost,
one using UK figures [252] and the other USA figures
[253], but the findings are similar, at £220 in the UK and
£179 (range £159–348) in the USA (Table 12). These co-
stings are sensitive to throughput. A reasonable through-
put per camera is 2,000 patients per year but this can be
increased to as much as 4,000 in high-volume centres by
running the camera 12 h per day and 6 days per week.
Cost-effectiveness analysis
Although randomised controlled and blinded trials are
often used to evaluate the cost-effectiveness of therapy,
this study design is difficult or impossible in the case of
diagnostic testing. However, some data have been de-
rived from decision analytical models and these have
demonstrated the cost-effectiveness of MPS both in pa-
tients presenting with stable chest pain syndromes [254]
and in pre-operative risk assessment [255]. Garber and
Solomon showed that in 55-year-old men presenting
with chest pain, a strategy of MPS proceeding to angiog-
raphy compared with exercise ECG proceeding to angi-
ography cost £25,000 per quality-adjusted life-year
(QALY) [256], a figure that is generally regarded as ac-
ceptable [257]. The benefit of MPS would have been
even greater if a more realistic model had been used,
since it was assumed that all patients with disease pro-
ceed to angiography, whereas, as demonstrated above, it
is possible to treat low-risk patients with CHD without
the need for angiography. Patterson et al. also found ini-
tial testing with MPS to be more cost-effective than the
exercise ECG although, again, the model assumed that
all patients with disease undergo angiography [258]. 
Kuntz found a higher incremental cost-effectiveness of
initial MPS over the exercise ECG of £34,250 in a 55-
year-old man with atypical chest pain but they used an
unrealistically low specificity of 64% for MPS and again
assumed that all patients with disease undergo angiogra-
phy [259]. It would be valuable to repeat these models
assuming that patients with abnormal but low-risk non-
invasive tests are treated medically in the first instance,
since the prognostic power of MPS is likely to lead to
even greater cost-effectiveness.
Interpretation of these numbers should be placed in
the context of other generally accepted medical interven-
tions. For example, coronary artery bypass grafting for
patients with triple-vessel coronary artery disease and se-
verely impaired left ventricular function costs £25,500
per QALY gained [260] and cholesterol-lowering thera-
py in a 60-year-old man with cholesterol of 7.5 mmol/l
costs approximately £30,000 per QALY [261]. Thus,
MPS appears to be a cost-effective use of resources com-
pared with other generally accepted medical procedures.
Mathematical simulations have the advantage of us-
ing data from diverse sources or from expert opinion, but
they are limited by a lack of real-world effectiveness da-
ta. However, two controlled clinical studies have demon-
strated savings for similar outcomes using MPS in pa-
tients presenting with chest pain. The EMPIRE study
compared patients presenting with stable chest pain syn-
dromes to centres that routinely use MPS and those that
do not in each of four European countries [252]. Diag-
nostic strategies using MPS were cheaper and equally ef-
fective compared with those that did not, both for the
costs of diagnosis and for overall 2-year management
costs, but patient outcome was the same (Fig. 6).
Table 12. Cost of common diagnostic tests calculated using prin-
ciples that estimate the true consumption of resources. Estimates
are shown for the UK (EMPIRE study) [252] and the USA [253]
EMPIRE USA average USA range 
(£) (£) (£)
Rest ECG 20
Exercise ECG 70
Rest echocardiography 100 55 39–207
CT 172 55–288
MPS 220 179 159–348
MRI 529 318–739
PET 771 582–891
Coronary angiography 1,100 1,097 516–2,873
CT, Computed X-ray tomography; MPS, myocardial perfusion
scintigraphy; MRI, magnetic resonance imaging; PET, positron
emission tomography
Fig. 6. The 2-year costs of diagnosis (dark grey) and management
(light grey) in patients without CHD but presenting with stable
chest pain syndromes, according to strategy of investigation and
type of hospital. The strategies of investigation are: 1, exECG-an-
gio; 2, exECG-MPS-angio; 3, MPS-angio; 4, angio. MPS, Regular
user of MPS; non-MPS, occasional user of MPS. [252]
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The END study was a larger (11,372 patients) registry
study with very similar findings of 30–40% savings in
costs over 2.5 years in patients with stable chest pain syn-
dromes undergoing initial MPS and selective angiogra-
phy (Fig. 7) [262]. An additional series of 9,521 patients
showed that MPS was more cost-effective than stress
echocardiography in patients with known CHD and stable
chest pain at $39,347 per life-year saved [263], and a sep-
arate modelling study also found MPS to be more cost-ef-
fective than stress echocardiography [264].
Other clinical studies indirectly support the cost-effec-
tiveness of MPS. In a US practice making routine use of
MPS, the number of patients with normal MPS proceed-
ing to angiography is 1% [265], whereas in a UK rapid
access chest pain clinic that makes little use of MPS, cor-
onary angiography rates are high and 56% of coronary
angiograms in women are normal [266]. It has been esti-
mated that routine use of MPS in this setting would re-
duce cost by £65,000 per year, mainly by reducing the
normal coronary angiography rate [267]. Similarly, in the
USA it has been estimated that about one-third of refer-
rals to coronary angiography are inappropriate [268].
Clinical outcomes
Modelling studies indicate that clinical outcome is im-
proved by MPS at a cost per QALY that is acceptable and
that life expectancy is increased by between 7 days and 2
years [255]. Because of the scale and nature of the studies
that would be required, it has been more difficult to con-
firm this finding in clinical studies, but in a re-analysis of
the END data [262] Shaw and colleagues have shown that
testing with initial MPS adds between 1 and 2 years of life
[269] and in a separate study they showed that MPS added
0.5 years compared with stress echocardiography [263].
Current clinical guidelines for MPS
This section reviews some of the current guidelines for
the use of MPS in CHD, which in most cases have been
based upon a review of the relevant evidence (Table 13).
Fig. 7. The 2.5-year costs of diagnosis (dark grey) and manage-
ment (light grey) in 11,372 patients presenting with stable chest
pain syndromes who underwent initial angiography or MPS with
selective angiography, according to low, intermediate or high pre-
test likelihood of CHD. [262]
Table 13. Guideline documents and statements
Statement Source Reference
American bodies
Guideline update for exercise testing, 2002 ACC/AHA [270]
Guidelines for clinical use of cardiac radionuclide imaging ACC/AHA/ASNC [271]
Guideline update for the management of patients with chronic stable angina, 2002 ACC/AHA [272]
The role of myocardial perfusion imaging in the clinical evaluation of coronary artery disease ASNC [273]
in women
Updated imaging guidelines for nuclear cardiology procedures: part 1 ASNC [274]
European bodies
Management of acute myocardial infarction in patients presenting with ST segment elevation ESC [243]
Management of acute coronary syndromes in patients presenting without ST segment elevation ESC [275]
British bodies
Investigation and management of stable angina: revised guidelines 1998 BCS/RCP [276]
National Service Framework for Coronary Heart Disease DoH [220]
Guidelines for tomographic radionuclide myocardial perfusion imaging BNCS/BNMS [277]
Guideline for the management of acute coronary syndromes without persistent ECG ST BCS/RCP [278]
segment elevation
ACC, American College of Cardiology; AHA, American Heart
Association; ASNC, American Society for Nuclear Cardiology;
ESC, European Society of Cardiology; BCS, British Cardiac Soci-
ety; RCP, Royal College of Physicians; DoH, UK Department of
Health; BNCS, British Nuclear Cardiology; BNMS, British Nucle-
ar Cardiology Society
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Diagnosis and assessment of stable chest pain
The superior diagnostic accuracy of MPS compared with
the exercise ECG is widely recognised in the setting of
stable chest pain syndromes and chronic stable angina
(Table 14). Both European and American guidelines rec-
ommend MPS in patients with an intermediate pre-test
likelihood of coronary artery disease. In the UK, the Na-
tional Service Framework for CHD does not give specif-
ic recommendations, although it does comment on spe-
Table 14. Recommendations for MPS in chronic stable angina or stable chest pain syndromes requiring investigationa
Body/guidelines General Unable to exercise Abnormal ECG Women
ACC/AHA stable Patients with inter- Intermediate likelihood Intermediate likelihood of CHD Indications for MPS
angina guidelines mediate likelihood of CHD (1/B) and ECG with pre-excitation (1/B), are similar in men
2002 [272] of CHD (2b/B) ST depression (1/B), ventricular and women
pacing (1/C), LBBB (1/B), digoxin 
or LVH with minor ST change 
(2b/B), these ECGs with low 
or high likelihood of CHD (2b/B)
ASNC updated Diagnosis or prognosis As per general LBBB specifically recommended No  comment
imaging guidelines in known/possible recommendations, 
[274] CHD but with pharmaco-
logical stress
ACC/AHA/ASNC To identify extent, Pharmacological Vasodilator stress with MPS MPS is “logical” 
guidelines for site and severity stress with MPS recognised as optimal test
clinical use of of CHD is “appropriate (mainly LBBB)
radionuclide option”
imaging 2003 [271]
ACC/AHA stress Low or intermediate Low or intermediate Vasodilator stress for LBBB, MPS if reduced 
testing guidelines likelihood of CHD: likelihood of CHD: paced rhythm, pre-excitation, exercise tolerance 
2002 exercise test with MPS pharmacological stress ST depression (>1 mm) or false positive 
with MPS exercise ECG 
suspected
ASNC consensus MPS if reduced MPS if abnormal resting ECG MPS if intermediate 
on women with IHD exercise tolerance risk exercise ECG,
in diabetic women,
or in those with 
reduced functional
capacity
BNCS/BNMS Assess patients with 
guidelines for suspected CHD
SPET [277]
NSF for Coronary MPS when diagnosis “Alternate test”, Other test may 
Heart Disease is uncertain e.g. thallium scan be needed
Standard
BCS/RCP Submaximal Pharmacological MPS may be first-line (B) MPS as first-line
guidelines for the exercise ECG MPS investigation
investigation of
stable angina [276]
ST depression with 
low-risk CHD
No ST change 
with high-risk CHD
Equivocal exercise 
ECG
Abbreviations as defined in Table 13 and the list of abbreviations
a 1, 2a, 2b, 3 = class of recommendation; A, B, C = level of evidence
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cific subgroups [220]. Current BCS guidelines suggest
that MPS is helpful after the exercise ECG if there is
equivocal ST segment change, a negative test with a high
pre-test likelihood of disease or a positive test with a low
pre-test likelihood [276]. The BNMS/BNCS guidelines
suggest that MPS is a useful procedure in most patients
with suspected coronary artery disease [277].
Women
All of the guidelines recognise the reduced accuracy of
the exercise ECG in women, but the degree to which
MPS is recommended as an alternative first-line investi-
gation, as opposed to a second-line investigation after
the exercise ECG, is variable. The American guidelines
suggest selective use [270, 272]. The American Society
of Nuclear Cardiology states that MPS should be consid-
ered in all symptomatic women with an intermediate
likelihood of CHD after an exercise ECG or as a first test
if the resting ECG is abnormal, in diabetics or if poor ex-
ercise capacity is predicted [273]. British guidelines are
conflicting. The National Service Framework proposes
an exercise ECG for nearly all patients and, although it
recognises problems with interpretation in women, it
does not specifically advise on MPS unless exercise is
not possible [220]. However, the BCS proposes MPS as
a first-line test in all women with suspected CHD [276].
Inability to exercise
All guidelines propose MPS with pharmacological stress as
a suitable test for the diagnosis of chest pain. Class 1 status
is given by the American guidelines when there is interme-
diate pre-test likelihood of disease or previous coronary re-
vascularisation [272]. In addition, vasodilator stress with
MPS is preferred to stress echocardiography in patients
with left bundle branch block (LBBB) or paced rhythm.
The BCS guidelines make pharmacological stress with
MPS the first-line investigation for this indication [276]
and the National Service Framework for Cardiovascular
Disease (NSF) indicates that alternatives to the exercise
ECG (such as “thallium scan”) should be available [220].
Abnormal resting ECG
ST segment displacement with exercise is an unreliable
indicator of ischaemia in patients with LBBB, ventricu-
lar pacing, resting ST segment depression greater than
1 mm or pre-excitation. Two of the American guidelines
recommend MPS with pharmacological stress for pa-
tients with LBBB or ventricular pacing on ECG (class I
indication) [270, 272] and MPS is recommended for pa-
tients with pre-excitation or resting ST segment change.
The initial test may be coronary arteriography if clinical
features suggest high risk. MPS is suggested for patients
taking digoxin, although this is not common to all of the
guidelines. In the UK, the NSF states that MPS is indi-
cated in patients with a high likelihood of a false positive
exercise ECG, and an abnormal resting ECG is probably
included in this statement [220]. The BCS suggests that
MPS should be the initial investigation in patients with
resting ECG abnormalities [276].
Assessment before or after revascularisation
MPS is an accurate method for assessing the haemody-
namic significance of known coronary lesions, identify-
ing the site for potential revascularisation and assessing
the result of previous coronary angioplasty or bypass
surgery (Table 15). The exercise ECG performs poorly in
Table 15. Recommendations for MPS with respect to revascularisation
Body Recommendations
ACC/AHA stable angina guidelines 2002 [272] Assess patients with previous PCI or CABG (1/Ba)
ASNC updated imaging guidelines [274] Assess significance of known coronary lesion/plan PCI site (1/B)
Evaluate revascularisation
Early assessment after PCI
ACC/AHA/ASNC guidelines for clinical use Identify ischaemia/target site for PCI (1)
of radionuclide imaging 2003 [271] Assess for restenosis after PCI (1)
Assess symptomatic patients after CABG (1)
Selected asymptomatic patients after CABG (1)
ACC/AHA stress testing guidelines 2002 MPS “more desirable” than exercise ECG after CABG
MPS better than exercise ECG after PCI but no specific recommendations
BNCS/BNMS guidelines for SPET [277] Assessment of significance of coronary stenoses
Assess adequacy of PCI and CABG procedures
CABG, Coronary artery bypass grafting; PCI, percutaneous coronary intervention; other abbreviations as defined in the list of abbreviations
a Class of recommendation/level of evidence
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these areas. Two of the American guidelines recommend
MPS to identify the target lesion for coronary interven-
tion and to assess symptomatic patients following bypass
surgery (class 1 indications) [270, 272]. These indica-
tions are also mentioned in the joint BCS/BNCS/BNMS
practice guidelines [277] but the area is not covered by
the BCS guidelines on angina or by the NSF.
Risk stratification after acute coronary syndromes
Non-ST elevation myocardial infarction
European guidelines are that MPS should be performed
for risk stratification after NSTEMI in patients who can-
not exercise, in those with unhelpful exercise ECG tests
and in women [275]. American guidelines also emph-
asise its use in low-risk medically stabilised patients. Re-
cent UK guidelines recommend MPS in stabilised pa-
tients who cannot exercise [278]. Otherwise the standard
exercise ECG is mainly suggested, although other stress
tests are alluded to.
ST elevation myocardial infarction
American guidelines recommend MPS for risk stratifica-
tion in low-risk patients following STEMI (Table 16).
This is a class 1 indication [271] but the exercise testing
guidelines [270] suggest that MPS should be used more
selectively, in patients with mildly abnormal exercise
ECGs or in those who have an uninterpretable ECG or
who cannot exercise. The European guidelines suggest
assessment of exercise tolerance and ischaemic burden
Table 16. Recommendation for MPS in acute coronary syndromes
Body NSTEMI STEMI
ASNC updated imaging guidelines [274] Risk stratification post ACS Risk stratification post MI
Exercise stress Exercise stress
Pharmacological stress if unable to exercise Pharmacological stress if unable to exercise
Early risk stratification post MI-vasodilator
stress
ACC/AHA/ASNC guidelines Assess degree and site of ischaemia/ Demonstration of stress ischaemia 
for clinical use of radionuclide culprit lesion (1)a post MI (1)
imaging 2003 [271] Risk stratification after medical Size of infarct or risk territory
treatment (2a) (rest study) (2a)
ACC/AHA stress testing Risk stratification in low-risk patients MPS after mildly abnormal standard 
guidelines 2002 [270] exercise ECG test
MPS first-line if abnormal ECG 
or inability to exercise, in presence
of moderately low risk
BNCS/BNMS guidelines for SPET [277] Determine prognosis after MI
European report on management Pre-discharge testing suggested 
of NSTEMI [275] for risk stratification
Pharmacological stress for poor 
exercise capacity
MPS for low-risk patients with 
inconclusive exercise ECG
European report on STEMI Risk stratification for low-risk 
management [243] and possibly intermediate-risk patients. 
MPS defines extent of ischaemia 
and is gatekeeper to invasive 
management
BCS/RCP guideline for ACS Pharmacological MPS if unable 
without ST segment to exercise
Elevation 2001 [278] Exercise ECG for others
Angiography for high-risk patients
NSTEMI, Non-ST segment elevation myocardial infarction;
STEMI, ST segment elevation myocardial infarction; ACS, acute
coronary syndromes
a Numbers in parentheses refer to the class of recommendation
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and indicate that an imaging technique is superior to the
exercise ECG [243].
Assessment of ischaemic left ventricular dysfunction
MPS is a key technique in the assessment of patients
with ischaemic left ventricular dysfunction. Both Euro-
pean and American bodies recommend the technique af-
ter STEMI in patients with poor systolic function [243,
271] (Table 17). Thallium is specifically mentioned by
the American guidelines for the assessment of myocar-
dial viability, although gated imaging using technetium-
99m tracers can be particularly helpful. The joint
BNCS/BNMS guidelines propose this as one of the four
main indications for MPS [277].
Service provision
This section focusses mainly on service provision in the
UK but the principles are relevant in other European
countries.
Current UK practice
The foregoing demonstrates that the effectiveness and
cost-effectiveness of MPS support its use for the diagno-
sis and management of patients with suspected and
known CHD. Accordingly, the technique is an integral
part of UK and other clinical guidelines and it has long
been used routinely in many centres. However, there is a
general perception among those familiar with the field
that the technique is not used to its full potential and that
service provision in the UK has three main problems:
1. MPS is either not available or not requested in pa-
tients where the evidence and guidelines suggest ben-
efit. An example might be the lack of nuclear cardiol-
ogy support for many rapid access chest pain clinics
[266, 267].
2. MPS is available but the waiting time is too long for
the test to be clinically useful.
3. MPS provision is not of a uniform high standard in all
centres.
MPS activity in the UK
Since 1988 the BNCS has conducted regular surveys of
nuclear cardiology practice. The 1988 [279], 1994 [280]
and 1997 [281] surveys are published and data from the
2000 survey are available on request. The number of
MPS studies performed per million population per year
(pm) has increased over this period at a linear annual rate
of 26% or at a compound rate of 12.5% (Fig. 8). Never-
theless, the figure for 2000 was still only 1,200 pm, with
a median number of studies per centre of 256 per year.
Comparative data from 1994 show that the UK figure
at this time, 560 pm, was significantly below the Europe-
an average of 2,200 pm and very small compared with a
comparable US figure of 10,000 pm (Fig. 9) [280].
Table 17. Recommendations for MPS for the assessment of ischaemic left ventricular dysfunction
Body Recommendation
ACC/AHA/ASNC guidelines for clinical use Assess myocardial viability in LV impairment, 201Tl suggested
of radionuclide imaging 2003 [271]
BNCS/BNMS guidelines for SPET [277] Assess myocardial viability and hibernation
European Report on STEMI management [243] MPS recommended to assess viability after angiography if LV impaired
Assess viability/ischaemia in most patients (imaging study preferred)
Fig. 8. Growth of MPS in the UK from BNCS surveys
Fig. 9. Numbers of MPS studies in selected countries in 1994 (ex-
cept where stated). (Adapted from references [280] and [290])
cols it is relatively straightforward to perform the techni-
cal aspects of the study, but experience is required when
reporting. A BNCS/BNMS audit of quality assurance in
MPS demonstrated that 81% of studies in the random
sample were technically of good or adequate quality, but
only 68% of reports were good or adequate. [282]. Most
of the reports considered inadequate were so assessed
because they over-reported artefact or were clinically ir-
relevant or misleading. Since this time the BNCS and
BNMS have concentrated their educational efforts on re-
porting skills through a combination of dedicated train-
ing meetings, symposia and training materials [283]. Al-
though the audit has not yet been repeated, the impres-
sion within the profession is that quality is improving.
The low utilisation of MPS in the UK most likely
arises from a combination of low perceived demand and
inadequate supply. In all but a handful of centres, MPS is
performed in general nuclear medicine departments, out-
side the direct experience of referring cardiologists and
in marked contrast to other cardiac investigations such as
echocardiography and angiography. It is unsurprising
that the test may not be requested even when it can be
clinically helpful, or that it is not available sufficiently
rapidly to assist with clinical management. This vicious
circle has been broken in a small number of high-volume
centres where clinically relevant studies of high quality
are provided. Growth in MPS is concentrated in these
high-volume centres, but the clinical effectiveness and
cost-effectiveness of MPS remain largely academic in
many hospitals that do not have access to a reliable nu-
clear cardiology service.
Estimate of need
If there is a perception of underutilisation of MPS in the
UK, how should correct usage be judged? Comparisons
with practice in other countries cannot adequately an-
swer this question but the UK is at the lower end of the
spectrum for both absolute and relative numbers of stud-
ies and it therefore behoves those concerned to justify
this position as an outlier.
Past recommendations
The BCS considered levels of provision of a number of
investigations in 1994 (Fig. 11) [284, 285]. In all cases
the recommended target was lower than the actual num-
ber of studies but for MPS the discrepancy was greatest,
with a recommendation of 2,200 pm compared with ac-
tual numbers of 560 pm. At this time the recommenda-
tion for revascularisations (percutaneous and surgical)
was 1,000 pm and, based upon this, the recommendation
for coronary angiography was 2,000 pm. The ratio of 2:1
was based upon the fact that angiography does not al-
ways proceed to revascularisation and a single interven-
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Actual waiting times
The BNCS 2000 survey found a mean waiting time of 20
weeks, with the low-volume centres having a somewhat
longer mean waiting time (27 weeks) than the high-vol-
ume centres (17 weeks) (Fig. 10). Many centres prior-
itise referrals according to clinical urgency and, for ex-
ample, at the largest UK centre, with 5,500 patients per
year, the actual waiting times are shown in Table 18. Tar-
get waiting times are almost achieved for urgent patients
but at the expense of the less urgent.
Nature and quality of MPS in the UK
The BNCS 2000 survey showed a move from dynamic
exercise to pharmacological stress, which is used in 77%
of all studies, and a move from thallium-201 to the tech-
netium-99m based tracers, which are now used in 59%
of all studies. Eight-eight percent of studies used emis-
sion tomography imaging, 22% used ECG-gated acquisi-
tion, and 38% were supervised or reported by a cardiolo-
gist.
Another factor influencing use of MPS is the quality
of studies. With modern equipment and published proto-
Table 18. Target and actual waiting times for MPS at Royal
Brompton Hospital, London
Clinical urgency Target waiting time Actual waiting time
Routine 6 weeks 20 weeks
Soon 3 weeks 12 weeks
Urgent 1 week 2 weeks
Immediate 1 day 2 days
Fig. 10. Histogram of waiting times for MPS from the BNCS
2000 UK survey
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tion may be associated with more than a single angio-
gram. The concept was that angiography acts as the
“gatekeeper” to revascularisation.
Estimation of need
The same concept can be used to estimate numbers of
MPS studies compared with angiograms. If intervention
in patients with CHD is normally performed either to re-
lieve symptoms or to improve prognosis and if objective
evidence of inducible ischaemia is required before inter-
vention, then angiography should normally be preceded
by MPS, at least in stable coronary disease. The same ra-
tio of 2:1 for MPS to angiography might therefore be a
reasonable estimate.
The UK Department of Health has set a target of
1,500 revascularisations per million per year [220], and
this is credibly related to population need although with
upper estimates of need being considerably higher [286].
In the UK in 2001, 2,600 non-interventional coronary
angiograms were performed per million, compared with
an estimated number of revascularisations of 1,161 per
million (684 pm PCIs + 477 pm CABG) [287]. Thus the
ratio of MPS to angiography to revascularisation is
1,200:2,600:1,161, contrasting sharply with correspond-
ing numbers in the USA in 1996 of 12,800:7,200:5,050
(Fig. 12) [288]. The most important contrast is not the
difference in scale but the difference in ratios. If it is as-
sumed that an optimal ratio of MPS to angiography to re-
vascularisation is in the region of 4:2:1, this implies a
target number of MPS studies of 6,000 pm compared
with the target number of revascularisations, or 5,200 pm
compared with the actual number of angiograms.
This analysis clearly makes a number of assumptions,
not least the presumed optimal ratios, and it is therefore
important to err on the side of caution. However, a target
for MPI studies of 4,000 pm is reasonable and it would be
consistent with practice in other large European countries.
Clinically appropriate waiting time
Table 19 shows selected second-phase waiting times tar-
gets from the NSF. These have not been achieved in all
centres but waiting time initiatives have successfully re-
duced the waiting times to intervention. No targets were
proposed for MPS except indirectly by requiring com-
pletion of diagnosis and assessment in rapid access chest
pain clinics within 2 weeks. Clearly an actual waiting
time for MPS of 20 weeks is inconsistent with these tar-
gets. Waiting time targets have been recommended in the
South East Thames region at 2 weeks for routine studies
and within 2 days for urgent studies [289]. This covers
the full range of nuclear medicine procedures, including
diagnostic and staging studies for malignancy. Against
this background, we propose that suitable waiting time
targets for MPS would be 6 weeks for routine studies
and 1 week for urgent studies.
Fig. 11. BCS recommended and actual numbers of procedures in
1994, adapted from reference [284]. Echo, Echocardiography; Ex
ECG, exercise electrocardiography; Holter, 24-h ECG; Angio, cor-
onary angiography; Revasc, myocardial revascularisation
Table 19. Second-phase NSF targets for waiting times [220]
GP referral to cardiologist 2 weeks
or rapid access chest pain clinic
Specialist investigation
General “Prompt”
Rapid access chest pain clinic 2 weeks
Decision to investigate to angiography 3 months
Decision to operate to PCI 3 months
Decision to operate to surgery
High risk 3 months
Others 6 months
PCI, Percutaneous coronary intervention
Fig. 12. Numbers of procedures performed in USA in 1996 and
UK in 2000. CAG, Coronary angiography; Revasc, myocardial re-
vascularisation
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